Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Opium (Opioid) Addiction develops after using opioids regularly for a period. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). Its signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping, and pain in the bones. The predisposing factors include age, personal history/ family history of substance abuse, cigarette dependency, and psychological stress.

The Opium Addiction pipeline market research report provides comprehensive information on the therapeutics under development for Opium Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium Addiction and features dormant and discontinued projects.

Key Targets in the Opium Addiction Pipeline Products Market

The key targets in the Opium Addiction pipeline products market are Mu Type Opioid Receptor, Kappa Type Opioid Receptor, Delta Type Opioid Receptor, Opioid Receptor, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Glutamate Ionotropic Receptor NMDA Type Subunit, Aldehyde Dehydrogenase, Neuronal Acetylcholine Receptor Subunit Alpha 3, Neuronal Acetylcholine Receptor Subunit Beta 4, and others.

Opium Addiction Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Opium Addiction Pipeline Products MarketThe key mechanisms of action in the Opium Addiction pipeline products market are Mu Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Agonist, Delta Type Opioid Receptor Antagonist, Opioid Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Delta Type Opioid Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, and others.

The key mechanisms of action in the Opium Addiction pipeline products market are Mu Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Agonist, Delta Type Opioid Receptor Antagonist, Opioid Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Delta Type Opioid Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, and others.

Opium Addiction Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the Opium Addiction Pipeline Products Market

The key routes of administration in the Opium Addiction pipeline products market are oral, subcutaneous, sublingual, intravenous, intramuscular, parenteral, transdermal, injection, nasal, buccal, and inhalational.

Opium Addiction Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Opium Addiction Pipeline Products Market

The key molecule types in the Opium Addiction pipeline products market are small molecule, conjugate vaccine, antibody, gene therapy, monoclonal antibody, synthetic peptide, and vaccine.

Opium Addiction Pipeline Products Market Analysis by Molecule Types

For more molecule type insights, download a free report sample

Major Companies in the Opium Addiction Pipeline Products Market

Some of the major companies in the Opium Addiction pipeline products market are BioCorRx Inc, Delpor Inc, DemeRx Inc, Alar Pharmaceuticals Inc, Cessation Therapeutics LLC, Gilgamesh Pharmaceuticals Inc, Indivior Plc, Lyndra Therapeutics Inc., Mind Medicine MindMed Inc, and Nirsum Laboratories Inc.

Opium (Opioid) Addiction Pipeline Products Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.